Mylan Recalls 15 Batches of Valsartan Globally- for the Treatment of Hypertension
Shots:
- Mylan has recalled globally- 6 lots of Amlodipine and Valsartan Tablets- USP (including the 5mg/160mg- 10mg/160mg- and 10mg/320mg strengths)- 7 lots of Valsartan Tablets- USP (including 40 mg- 80 mg- 160 mg- and 320 mg strengths) and 2 lots of Valsartan and Hydrochlorothiazide Tablets- USP (320mg/25mg strength) - detected with traces of N-nitrosodiethylamine (NDEA)
- The voluntarly recall is done for the lots of Valsartan- distributed between Mar- 2017 and Nov- 2018. European Union authorities has already ban sales of valsartan few days’ back
- Valsartan is a combination of amlodipine or hydrochlorothiazide indicated for the treatment of high blood pressure- heart failure and in reduction of cardiovascular mortality
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
